DOQUALAST

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H8N2O3
Molecular Weight	240.2142
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC2=C(C=C1)N=C3C=CC=CN3C2=O

InChI

InChIKey=HMZDSBSMNLBGIW-UHFFFAOYSA-N

InChI=1S/C13H8N2O3/c16-12-9-7-8(13(17)18)4-5-10(9)14-11-3-1-2-6-15(11)12/h1-7H,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C13H8N2O3
Molecular Weight	240.2142
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2907188 | https://www.ncbi.nlm.nih.gov/pubmed/3814221 | Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 920, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ

Doqualast is an antiasthmatic and antiallergic agent. It has a mode of antiallergic action similar to that of disodium cromoglycate and inhibits antigen-induced mediator release by interfering with the calcium transport required for histamine secretion across the mast cell membrane. In rabbits, no embryotoxic or teratogenic effects of doqualast were observed. The concomitant use of doqualast and theophylline might cause drug interaction. Doqualast is thought to increase the blood free fraction of concomitantly used theophylline and to accelerate elimination of theophylline from blood.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
histamine secretion 4 Target ID: GO:0001821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2434111	Inhibitor 8504

PubMed

Title	Date	PubMed
[Pilot study of the action of Doqualast on dietary hyperuricemia in volunteers].	1989-09	2574040
[Protective effect of Sm 857 on allergen-induced immediate bronchoconstriction].	1988-11	2907285
Teratogenicity of the antiallergic Sm 857 SE in rats versus rabbits.	1988-10	2907188
Evaluation of different drugs in two models of immediate hypersensitivity.	1988-03	2899148
[Comparison of the anti-allergic and anti-asthmatic effects of SM 857 (Doqualast) and DNCG].	1987-02	3106950
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on immediate allergic reactions.	1986-11	2434109
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on type I allergic reactions.	1986-11	2434110
Immunopharmacological actions of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid. Effects on type I hypersensitivity reactions in human leukocytes and in human and monkey lungs.	1986-11	2434111
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on bronchial and cutaneous allergic responses to ascaris in dogs.	1986-11	2434112
Effect of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid on inflammatory reactions and platelet aggregation.	1986-11	3493011
[Protective effect of Sm 857 (Doqualast) in allergic bronchial asthma].	1986-11	3543921
Immunopharmacological actions of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid. Effects on immunological reactions in mice and in humans.	1986-11	3814220
Study of drug interaction between the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid and theophylline.	1986-11	3814221

Patents

Sample Use Guides

In Vivo Use Guide

Single dose 50 mg/kg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 10:00:29 GMT 2025` Edited by `admin` on `Wed Apr 02 10:00:29 GMT 2025`
Record UNII	N8F510M76F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DOQUALAST

Official Name

English

doqualast [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29712